MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
AGEN stock logo

AGEN

Agenus Inc.

$4.97
-0.04
 (-0.8%)
Exchange:  NASDAQ
Market Cap:  206.963M
Shares Outstanding:  8.625M
Delayed data
Calculate AGEN Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Biotechnology
   
CEO:  Garo H. Armen
Full Time Employees:  81
Address: 
3 Forbes Road
Lexington
MA
02421-7305
US
Website:  https://www.agenusbio.com
Agenus Inc. is a clinical-stage biotechnology firm operating globally, dedicated to the discovery and development of immuno-oncology therapies. The company’s innovative technological arsenal includes Retrocyte Display, a sophisticated antibody expression platform designed to identify fully human and humanized monoclonal antibodies, alongside other proprietary display technologies. Agenus is also actively involved in vaccine development programs, featuring the Prophage vaccine candidate and QS-21 Stimulon, a widely recognized saponin-based vaccine adjuvant. Its robust and diverse pipeline of therapeutic candidates targets various immune checkpoints and cancer pathways. Notable assets in clinical development include: Balstilimab: An anti-PD-1 antagonist that has successfully completed Phase II trials for the treatment of second-line cervical cancer. AGEN1181: A monospecific anti-CTLA-4 antibody currently undergoing Phase 1/2 clinical evaluation. AGEN2373: An anti-CD137 monospecific antibody in Phase 1 clinical trials. AGEN1423: A bi-functional anti-CD73/TGFß TRAP antibody, engineered to modulate the tumor microenvironment, which has concluded Phase 1 studies. AGEN1777: An anti-TIGIT bispecific antibody. AGEN1327: A human monoclonal antibody. INCAGN1876: An anti-GITR monospecific antibody. INCAGN1949: An anti-OX40 monospecific antibody. INCAGN2390: An anti-TIM-3 monospecific antibody. INCAGN2385: An anti-LAG-3 monospecific antibody. MK-4830: A monospecific antibody engineered to target ILT4. AGENT 797: An iNKT cell therapy, currently in Phase 1 for solid tumors, multiple myeloma, and viral ARDS, with ongoing clinical investigation for hematological malignancies and multiple myeloma/B cell indications. AGEN1884: A first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. utilizes a portfolio of trademarks, including ASV, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon, alongside its own company name. Strategic alliances are maintained with partners such as Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. Established in 1994, the company originally operated as Antigenics Inc. before rebranding to Agenus Inc. in January 2011. Its corporate headquarters are situated in Lexington, Massachusetts.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/12 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue156,314103,463114,196
Gross Profit-81,366-52,55133,836
EBITDA-145,924-101,30262,189
Operating Income-159,549-120,475-20,556
Net Income-245,761-227,212115

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets313,913226,271226,798
Total Liabilities462,295532,695504,659
Total Stockholders Equity-160,331-326,380-271,111
Total Debt78,01294,870334,899
Cash and Cash Equivalents76,11040,4372,998

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-224,202-158,315-158,315
Capital Expenditure-9,954-576-576
Free Cash Flow-234,156-158,891-158,891
Net Income-245,761-232,271-232,271
Net Change in Cash-101,564-35,708-35,708

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)216,294.148Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)260,505.851Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)238,400Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-115,663.563Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-96,033.743Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-105,848.653Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)-8,662.703Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)-6,798.976Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)-7,730.840Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)119,368.868Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)143,768.516Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)131,568.692Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)-0.260Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)-0.230Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)-0.290Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)1Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
1.68
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
2.9
?Enterprise Value
 (TTM)
: 
478.096M  ?EV/FCF
 (TTM)
: 
-5.46
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-23.05%  ?ROIC
 (TTM)
: 
10.53%
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
-1.38
?P/B
 (TTM)
: 
-0.86  ?Current Ratio
 (TTM)
: 
0.38

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
7.42Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about AGEN valuation

Is Agenus Inc. (AGEN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Agenus Inc. (AGEN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is AGEN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AGEN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is AGEN’s P/E ratio?

You can see AGEN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for AGEN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is AGEN a good long-term investment?

Whether AGEN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

AGEN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

-0.8
MARKETSnap

Trading Metrics:

Open: 5.04   Previous Close: 5.01
Day Low: 4.94   Day High: 5.47
Year Low: 2.71   Year High: 8.7
Price Avg 50: 3.48   Price Avg 200: 3.67
Volume: 1.961M   Average Volume: 3.933M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
14-07-2026 13:01
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
Agenus shares surge as company secures up to $340M to advance colon cancer trial
13-07-2026 13:11
Agenus shares surge as company secures up to $340M to advance colon cancer trial
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing
13-07-2026 10:02
Agenus Pivots to Phase 3 Colon Cancer Trial, Lines Up $340 Million Financing
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
13-07-2026 06:00
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
26-05-2026 13:35
How Agenus' Pipeline Progress Unlock Its Next Growth Phase
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
21-05-2026 17:00
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read